Complex Clinical Trials (CCTs) have the potential to accelerate drug development and enable patients to get timely access to transformative therapies.
The EFPIA Pipeline Review has found that in 2020 alone, around 5,000 clinical trials were initiated to investigate and develop new therapies and vaccines. Almost 50% of therapies in development are new substances, with 40% of the pipeline targeting rare diseases, and groundbreaking cell and gene therapies growing in importance. This exciting new wave of medical innovation will play a key role in addressing the challenges faced by patients and healthcare systems. To coincide with the publication of EFPIA’s annual “Pipeline Review”, we are organising a high-level panel discussion around the latest medical research outcomes.